Qube Research & Technologies Ltd Grows Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Qube Research & Technologies Ltd raised its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 84.4% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 14,209 shares of the biotechnology company’s stock after buying an additional 6,505 shares during the period. Qube Research & Technologies Ltd’s holdings in United Therapeutics were worth $2,549,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Clean Yield Group purchased a new position in shares of United Therapeutics in the 2nd quarter valued at about $27,000. Eaton Vance Management purchased a new position in shares of United Therapeutics in the 1st quarter valued at about $30,000. Evermay Wealth Management LLC purchased a new position in shares of United Therapeutics in the 2nd quarter valued at about $67,000. Healthcare of Ontario Pension Plan Trust Fund increased its stake in shares of United Therapeutics by 369.4% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 399 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 314 shares in the last quarter. Finally, Advisory Services Network LLC purchased a new position in shares of United Therapeutics in the 2nd quarter valued at about $90,000. Institutional investors and hedge funds own 94.95% of the company’s stock.

In other United Therapeutics news, Director Christopher Causey sold 2,610 shares of the business’s stock in a transaction that occurred on Friday, August 6th. The stock was sold at an average price of $210.00, for a total value of $548,100.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, September 2nd. The shares were sold at an average price of $210.94, for a total value of $1,265,640.00. Following the completion of the sale, the executive vice president now directly owns 42,369 shares in the company, valued at approximately $8,937,316.86. The disclosure for this sale can be found here. Insiders sold 20,610 shares of company stock worth $4,181,340 over the last quarter. 12.10% of the stock is currently owned by insiders.

Shares of United Therapeutics stock opened at $186.09 on Thursday. United Therapeutics Co. has a 1-year low of $108.16 and a 1-year high of $216.90. The stock has a market cap of $8.36 billion, a P/E ratio of 18.08 and a beta of 0.49. The stock’s 50 day simple moving average is $201.71 and its 200-day simple moving average is $193.01. The company has a debt-to-equity ratio of 0.22, a current ratio of 7.44 and a quick ratio of 7.15.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 4th. The biotechnology company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.02 by $0.63. United Therapeutics had a return on equity of 13.69% and a net margin of 29.60%. The firm had revenue of $446.50 million for the quarter, compared to analysts’ expectations of $378.54 million. During the same period in the prior year, the firm posted $3.68 earnings per share. The firm’s quarterly revenue was up 23.3% on a year-over-year basis. As a group, research analysts expect that United Therapeutics Co. will post 11.07 EPS for the current fiscal year.

Several equities analysts recently weighed in on the company. Zacks Investment Research lowered United Therapeutics from a “hold” rating to a “sell” rating and set a $192.00 price target for the company. in a research note on Tuesday, July 20th. Argus upgraded United Therapeutics from a “hold” rating to a “buy” rating and set a $205.00 price objective for the company in a research note on Wednesday, July 14th. One investment analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $220.78.

United Therapeutics Company Profile

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.

Featured Story: Dead Cat Bounce

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.